RxDoctor Payments Data

Kevin Stiver

Interventional Cardiology · Columbus, OHNPI 1356502280

Payments from drug & device makers

$37,350in general payments, 2019–2025

Across 217 payments — averaging $172.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Circulation Inc$30K
  • Boston Scientific$3K
  • Medtronic$778
  • Edwards Lifesciences$474
  • Abbott$333
  • Penumbra, Inc.$273
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$10,36328%
  • Speaking & faculty fees$17,65047%
  • Travel & lodging$2,6837%
  • Food & beverage$6,65518%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,350 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$122,370
Medicare patients
608
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$96,325
XareltoRivaroxaban31$33,504
Repatha SureclickEvolocumab49$29,242
EntrestoSacubitril/Valsartan18$21,380
FarxigaDapagliflozin Propanediol12$9,556
Ranolazine ErRanolazine20$1,565
Atorvastatin Calcium162$1,421
ClopidogrelClopidogrel Bisulfate158$1,011
Metoprolol Succinate72$998
Carvedilol88$553
Losartan Potassium58$438
Amlodipine Besylate60$390
Potassium Chloride15$369
Isosorbide Mononitrate ErIsosorbide Mononitrate44$355
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$213$33,50431 claims
NovartisEntresto$138$21,38018 claims
AstraZenecaFarxiga$74$9,55612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →